Case report: A family with 5 members age ranges between 13 to 77, both male and females, one with preexisting renal impairment, SARS CoV-2 positive with mild to moderate category were treated with VKM along with the specific dietary practice. The drug was consumed at home quarantine. Real-Time RT PCR from oropharynx swab, X-ray/CT scan chest, hematology, renal function, liver function, body temperature and oxygen saturation were assessed. Blood parameters were repeated after completion of therapy to assess the safety aspect of mercury drug. Chemical profile of the drug was done using Gas chromatography-mass spectrometry and inductively coupled plasma mass spectrometry.
Results: With the first dose, the oxygen saturation was improved. Within 3 days of therapy, all symptoms (fever, body pain, cough, and loss of taste) were normalized and renders the Real-Time RT PCR negative for COVID-19. There was no observed side effects and damage to renal and liver. The drug contains 22% of mercury along with a 9-Octadecenoic acid-(E), 1H-Imidazole, 4,5-dihydro-2-(phenylmethyl) and 9,12-Octadecadienoic acid (Z,Z)- as major organic compounds.
Conclusion: Vajra kandi maathirai might be a safe drug to manage COVID-19 patients. Rigorous research is required to discover new antiviral molecules from this formulation.
STUDY DESIGN: Secondary analysis of a large dataset multi-country observational study.
METHODS: We used a four-pronged analysis approach to investigate whether personal history of infectious and parasitic diseases is related to self-reported health, measured with a single item.
RESULTS: Three of the four analyses found a small positive effect on self-reported health among those reporting a history of pathogen exposure. The meta-analysis found no support but large heterogeneity that was not reduced by two classifications of countries.
CONCLUSION: Personal history of infectious and parasitic diseases does not reduce self-reported health across a global sample.